MUMBAI, India, Aug. 8 -- Intellectual Property India has published a patent application (202411004626 A) filed by Council Of Scientific And Industrial Research, New Delhi, on Jan. 23, 2024, for 'small molecules targeting pcsk9-mediated dyslipidemia.'
Inventor(s) include Ajay Kumar Srivastava; Manoj Kumar Barthwal; Imran Siddiqi; Mohammad Wahajuddin; Manish Kumar Chourasia; Srikanta Kumar Rath; Manju; Anamika Yadav; Amit Kumar; Heena Agarwal; Gaurav Sharma; Nidhi Rajput; Smriti; Sahahuddin Ahmad; Shagun Krishna; Sandeep Kumar Singh; and Deepak Sharma.
The application for the patent was published on Aug. 8, under issue no. 32/2025.
According to the abstract released by the Intellectual Property India: "The present invention relates to sulfonohydrazide compounds and their analogues as selective PCSK9 pathway inhibitors, their derived analogues and pharmaceutically acceptable and active forms of different kinds that can find application in both prophylactic and therapeutic use for various diseases and disorders where cardiovascular and related systems may be affected that will subsequently affect the morbidity and mortality such as but not limited to dyslipidemia, diabetes, vascular and cardiac dysfunction, hepatic and adipocyte alterations and dysfunction and renal and immune functions. The invention also relates to process for the manufacture of the said compounds and pharmaceutical compositions containing them and their use. CDRI lead compound S-017-622, S017-0842, S017-0844 demonstrate significant in vitro and in vivo anti-hyperlipidaemic activity. portrays significant anti-hyperlipidaemic activity by lowering Total Cholesterol, Total Glyceride and LDL-C in hamster and guinea pig model of hyperlipidemia."
Disclaimer: Curated by HT Syndication.
